Search results for the GEO ID: GSE7322
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM174654
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 1 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma untreated K422 control cells
GSM174657
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 2 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma untreated K422 control cells
GSM174658
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 3 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma untreated K422 control cells
GSM174659
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 4 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma untreated K422 control cells
GSM174660
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 5 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma untreated K422 control cells
GSM174661
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 1 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174662
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 2 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174663
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 3 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174664
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 4 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174665
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 5 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174672
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 24 h, sample 1 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174673
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 24 h, sample 2 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174674
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 24 h, sample 3 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174675
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 24 h, sample 4 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174676
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 24 h, sample 5 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174677
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 1 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174690
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 2 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174691
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 3 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174692
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 4 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174693
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 5 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174694
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 24 h, sample 1 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174695
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 24 h, sample 2 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174696
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 24 h, sample 3 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174697
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 24 h, sample 4 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174698
GPL201
Alpha-irradiation with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 24 h, sample 5 Cell line Karpas 422 (K422) derived from a 73 year old woman with a B cell non-hodgkin´s lymphoma Bi-213-CD20-Rituximab irradiated K422 cells
GSM174821
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 1 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 3 untreated immunomagnetically selected primary CD19+ B-cells
GSM174822
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 2 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 1 untreated immunomagnetically selected primary CD19+ B-cells
GSM174823
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 3 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of a healthy donor untreated immunomagnetically selected primary CD19+ B-cells
GSM174824
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 4 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 3 untreated immunomagnetically selected primary CD19+ B-cells
GSM174825
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 5 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of a healthy donor untreated immunomagnetically selected primary CD19+ B-cells
GSM174826
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 6 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 3 untreated immunomagnetically selected primary CD19+ B-cells
GSM174827
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 7 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 4 untreated immunomagnetically selected primary CD19+ B-cells
GSM174828
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab control 8 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 2 untreated immunomagnetically selected primary CD19+ B-cells
GSM174867
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 1 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 3 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174875
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 2 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 3 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174876
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 3 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 2 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174877
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 4 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 2 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174878
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 5 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 2 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174879
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 6 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 1 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174880
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 100 µCi, 46 min, sample 7 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 4 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174881
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 1 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 3 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174882
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 2 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 3 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174892
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 3 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 4 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174893
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 4 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 4 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
GSM174894
GPL201
Alpha-irradiated primary CD19+ B-cells with the radioimmuno-conjugate Bi-213-CD20-Rituximab 200 µCi, 46 min, sample 5 Primary CD19+ B-Cells Immunomagnetically selected from peripheral blood of healthy donor 1 Bi-213-CD20-Rituximab irradiated primary CD19+ B-cells
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes